[Experimental study of the anti-tumor effects of directly administered packaging cell line of retroviral vector carrying IL-12 gene on hepatoma].
OBJECTIVE
To study the inhibitory effects of vivo directly administered packaging cell line of retroviral vector carrying mouse interleukin-12(mIL-12) on the growth of the vivo established hepatoma and to explore a new way for hepatoma gene therapy.


METHODS
Retroviral vector carrying mIL-12 gene was constructed. The vector was transfected to retroviral packaging cell line. Then the cell was injected intra-peritoneally and locally into hepatoma tissues or intrasplenally to observe its effects on the growth of hepatoma and the changes of immunological function in rats. Its toxic effects were also documented.


RESULTS
In treatment group, the rats survived permanently with the ratio of the packaging cell to hepatoma cell being less than 1:10, while the survival time of rats was only prolonged when the ratio was more than 1:10. In groups treated locally in the hepatoma tissue or intrasplenally, the rats survived permanantly with the packaging cell line given on the first or the third day, while the rats survived only longer with the packaging cell line given on the fifth or the seventh day. The immunological study showed that the number of hepatoma infiltrating lymphocytes, mainly composed of NK cell and cytotoxic T cell, was increased in the treatment group. The pathological study showed thicking of the vascular wall and sternosis of vascular cavity in hepatoma tissue in the treatment group.


CONCLUSIONS
The directly injected packaging cell line in vivo carrying mIL-12 gene via retroviral vector inhibits the growth of hepatoma. The therapeutical effects of early administration are superior to later one. Direct injection via spleen is a new, safe and effective way for hepatoma therapy with.
Yang
J
J
Tumor Immunology and Gene Therapy Center, Eastern Institute of Hepatobiliary Surgery, Shanghai 200438.
Qian
Q
Q
Xue
H
H
D000818:Animals; D002460:Cell Line; D015316:Genetic Therapy; D005822:Genetic Vectors; D018664:Interleukin-12 / Q000235:genetics* / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D051381:Rats; D012190:Retroviridae / Q000235:genetics; D014162:Transfection; D014407:Tumor Cells, Cultured
D018664:Interleukin-12